PMC3573800_01
a, b OCT findings prior to IVB injection. Central foveal thickness was 568 and 662 microm in OD and OS, respectively.
cop-0004-0007-g01.jpg
PMC3573800_01_cop-0004-0007-g01.jpg
F1
Optovue Inc., Fremont, Calif., USA), was 568 and 662 microm in OD and OS, respectively (fig. 1a, b). OCT analysis was performed in macular thickness map and 6-radial line modes.
a, b Findings 1 month after IVB injection. Central foveal thickness increased to 559 and 724 microm in OD and OS, respectively, due to VMT, as revealed by OCT.
cop-0004-0007-g02.jpg
PMC3573800_01_cop-0004-0007-g02.jpg
F2
OD and OS, respectively. One month after IVB injection, VA decreased to 0.1 and 0.2, and CFT increased to 559 and 724 microm in OD and OS, respectively, due to VMT, as revealed by OCT (fig. 2a, b).
a, b One month after IVTA injection, VMT was released, as revealed by OCT. Central foveal thickness was 163 and 181 microm in OD and OS, respectively.
cop-0004-0007-g03.jpg
PMC3573800_01_cop-0004-0007-g03.jpg
F3
OD and OS, respectively, 1 week after IVTA injection. One month after IVTA injection, VMT was released, as revealed by OCT, and CFT was 163 and 181 microm, and VA was 0.5 and 0.8 in OD and OS, respectively (fig. 3a, b).
a, b Six months after IVTA injection, central foveal thickness was 163 and 153 microm in OD and OS, respectively.
cop-0004-0007-g04.jpg
PMC3573800_01_cop-0004-0007-g04.jpg
F4
Six months after IVTA, CFT was 163 and 153 microm, and VA was 0.7 and 0.9 in OD and OS, respectively (fig. 4a, b).